Anika Therapeutics Inc (ANIK) — 分析摘要
Anika Therapeutics Inc(ANIK)的市值为209.83百万美元,最近一年的营收同比增长了-5.9%。净利润率为-9.6%。当前市盈率为-19.0倍。
核心要点
- 营收同比变化-5.9%
- 净利润率-9.6%
- 市盈率-19.0倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,ANIK的营收增长为-5.9%,市盈率为-19.0倍。
Anika Therapeutics Inc (ANIK)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
营业利润率为 -10.5% — 经营亏损显著
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
235
总部
BEDFORD, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。